DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
BD's Onclarity HPV PMA Submission to Boost Women's Health
by Zacks Equity Research
Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.
San Gorgonio Hospital Picks Allscripts Sunrise Community Care
by Zacks Equity Research
Allscripts' (MDRX) Sunrise Community Care is an Azure-hosted platform offering clinical, financial and ambulatory content.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
NextGen's Medfusion Buyout to Improve Patient Experience
by Zacks Equity Research
NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.
5 Relative Price Strength Stocks to Buy for Optimum Returns
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Dexcom, Fortinet and Agnico Eagle
A Struggle to Find Revenue Growth: Global Week Ahead
by John Blank
About 90% of S&P 500 companies have reported results as of Friday, Nov. 8th. 72.5% have beaten EPS estimates. Only 57.9% beat revenue estimates. A low Q3 revenue beat number (57.8%) is worrisome!
What Makes DexCom (DXCM) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
DexCom (DXCM) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom (DXCM) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.
DexCom (DXCM) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) Q3 earnings is likely to reflect top-line growth and rising global awareness of the company's real-time CGM.
DexCom's (DXCM) New G6 Pro CGM System Gets FDA Approval
by Zacks Equity Research
FDA approval for DexCom's (DXCM) G6 Pro boosts the company's broad product spectrum.
Stocks & ETF to Invest in Healthcare Robotics and Innovation
by Neena Mishra
HTEC is poised to benefit from rapid advances in health-care technology
Stocks & ETF to Invest in Healthcare Robotics and Innovation
by Neena Mishra
HTEC is poised to benefit from rapid advances in health-care technology.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
IoMT Becomes the Buzzword in New Age MedTech Investing
by Urmimala Biswas
Increasing adoption of cloud platforms, phones, phablets, tablets and other smart devices as well as apps is making acceptance of IoMT easier among the masses.
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.
DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
DexCom (DXCM) has various favorable factors to maintain the current high.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. However, contraction in gross margin remains a woe.
DexCom (DXCM) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
by Zacks Equity Research
Solid growth in emerging markets is expected to be an added positive this earnings season.
What's in the Offing for DexCom's (DXCM) Earnings in Q2?
by Zacks Equity Research
Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.
DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Internet of Things Stocks to Buy for July
by Benjamin Rains
Today we've highlighted three, Zacks buy-ranked stocks with growing IoT businesses that investors might want to consider at the moment...